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Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as
chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only
36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further
chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and
length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular
biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the
heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to
date in tackling a more general target applicable to ovary cancer—angiogenesis.
MECHANISMS OF ANTI-ANGIOGENESIS
Angiogenesis is a requirement to enable cancer growth. To promote
vascular sprouting, an angiogenic switch is ‘flipped’ that promotes
factors such as vascular endothelial growth factor (VEGF),
fibroblast growth factor (FGF) and angiopoietins and down-
regulates anti-angiogenics such as thrombospondin-1 and angios-
tatin. Other mechanisms also exist to vascularise growing cancers
such as vessel co-option, mimicry and intussusceptive angiogenesis.
An alternative approach to thwarting angiogenesis is to disrupt
the newly established vessels supplying the cancers by vascular
disruptive agents (VDAs). These generally cause rapid blood vessel
shutdown (within minutes) and subsequent tumour necrosis.
Strategies such as photodynamic therapy and radiofrequency
ablation, that directly damage tumour masses can be considered
VDAs (they also damage existing blood vessels), as are some
cytotoxics such as vinca alkaloids that inhibit spindle formation
causing cell-cycle arrest in the rapidly dividing endothelial cells as
well as malignant populations.
Anti-angiogenic agents such as VEGF/PDGF/FGF inhibitors have
been developed, of which the most successful to date is bevacizumab,
a humanised monoclonal antibody that inhibits the binding of
VEGF to its receptors, VEGFR-1 and VEGFR-2. Neutralising the
biological activity of VEGF inhibits the formation of new tumour
vessels, causing regression of the remaining tumour vasculature. This
slows tumour growth and metastasis (Jain, 2005). Preclinical and
early clinical studies show resistance to VEGF inhibition occurring
quite quickly and pure VEGF inhibitors such as bevacizumab are
best used in conjunction with chemotherapy. However, in contrast
to most other anti-vascular agents (Rustin et al, 2003), bevacizumab
has shown single-agent activity in ovarian cancer (Burger et al, 2007;
Cannistra et al, 2007), but not in many other solid tumour types
(Cobleigh et al, 2003; Sandler et al, 2006; Giantonio et al, 2007).
BEVACIZUMAB IN FIRST-LINE OVARIAN CANCER
Two pivotal studies involving bevacizumab treatment with
concomitant standard (3-weekly carboplatin and paclitaxel)
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chemotherapy in patients with newly diagnosed ovarian cancer were
recently published—ICON7 and GOG218 (Burger et al, 2011; Perren
et al, 2011). Both studies incorporated maintenance bevacizumab for
set periods of time after the completion of six cycles of chemotherapy.
Table 1 details the similarities and differences between the patient
populations, therapy administered and outcomes of these studies. In
both studies, the advantage of bevacizumab therapy stopped 10
months after the cessation of treatment. In ICON7, control and
research arm curves met at 22 months; bevacizumab was
administered for a total of 12 months. In GOG218, control and
research arm curves met at a later time point of 25 months; but
bevacizumab was administered for a total of 15 months. Maintenance
treatment with bevacizumab extended the length of PFS (Po0.001).
In GOG218, progression was defined on the basis of rising
CA125 alone as well as RECIST and symptomatic relapse, resulting
in a PFS of 10.3 vs 14.1 months in favour of maintenance
bevacizumab. If however only RECIST and symptomatic relapse
are considered, the PFS increased from 12.0 months in the placebo
arm to 18.0 months in the maintenance bevacizumab arm. Figure 1
shows that this difference in PFS was very similar to that shown in
the high-risk subgroup of ICON7 where CA125 was not taken into
account. However, this may not be entirely reliable as the number
of patients censored for CA125 is different in each GOG218 study
arm. Unfortunately due to 440% crossover, the overall survival
(OS) benefit of bevacizumab will never be accurately determined
from the GOG218 study.
Table 1. Phase III bevacizumab trials in ovary cancer
GOG218 first-line ICON7 first-line OCEANS plat-sens relapse
Primary end point PFS (defined by rising CA125/RECIST/
clinical deterioration)
PFS PFS
Secondary end
points
(OS was planned, but unlikely to be useful
due to cross over effect.), QoL
OS, response rate OS, ORR, median duration of response
Population 1873 1528 484
Stratification
Stage/debulking Stage III o1 cm vs stage III 41cm vs
stage IV
Stages I–III debulked p1cm vs I–III
debulked 41cm vs IV and inoperable
stage III
Surgery at relapse vs no surgery at relapse
Other GOG PS 0 vs GOG PS 1/2 Time post op to start chemotherapy
(o4 vs 44 weeks after surgery)
Plat.-free interval (6–12 vs 412 months)
GCIG group
Chemo/Bev
duration in
experimental arm(s)
Carbo AUC66 Paclitaxel 175mgm2
6þBev 15mg kg1 or placebo during/
after chemo for 15 months max
Carbo AUC5/66 Paclitaxel
175mgm2 x 6þBev 7.5mg kg1
during/after chemo for 12 months max
Carbo AUC 4 q 3w Gem 1gm 2 d1, 8 X 6 (up
to 10) þ / Bev 15mgkg 1 or placebo during/
after chemo to PD (median 12 bev/10 placebo)
Stopping rules—
rising CA125
RECIST/symptoms
Stop Bev if CA125 rising (GCIG criteria) Stop Bev if RECIST PD or symptoms
CA125 not used to denote PD
RECIST PD
CA125 not used to denote PD
Crossover to bev 28% o2.5% NR
Results
OS (NS trend, unlikely as crossover) (Overall awaited) FIGO III41 cm/IV:28.8
vs 36.6 months, HR:0.64. All stages 17.4
vs 19.8
(Immature 29.9 vs 35.5 months)
PFS (months control
vs bev arms)
All stages 10.3. vs 14.1 in maint. bev. arm,
when censored for CA125-only events;
12.0 vs 18.0
FIGO III 41 cm/IV: 10.5 vs 15.9 8.4 vs 12.4
ORR (%) NR 48% vs 67% in those with measurable
disease (n¼ 118 vs 168) Po0.0001
57.4 vs 78.5% (bev)
Toxicity
GIP (% in control
vs bev arms)
NS difference between arms
(1.2 vs 2.8/2.6)
NS difference (o1 vs 1) 2 patients 42 months after last dose bev
Inc BP with Bev
(% XG2)
17% (Maintenance) 15.3% 17% (grade X3)
Proteinuria (%XG3) NS (1.6%) NS (0.5%) 9%
Other (%XG3) 12% more XG2 abdo pain, bev
maintenance
None reported None reported
o1–1.1% inc incidence VTE/non-CNS
bleeds in bev maint
o1–2.6% inc incidence ATE/VTE/
non-CNS bleeds in bev
1–5% inc incidence of ATE/VTE/non-CNS
bleeds
Abbreviations: ATE¼ arterial thromboembolism; Bev¼bevacizumab; BP¼blood pressure; CNS¼ central nervous system; GCIG¼gynaecological cancer intergroup; GIP¼gastrointestinal
perforation; GOG¼gynaecological oncology group; NR¼ not reported; NS¼ non-significant; ORR¼overall response rate; OS¼overall survival; PD¼progressive disease; PFS¼progression-
free survival; plat.¼platinum; PS¼performance status; QoL¼quality of life; RECIST¼ radiology; VTE¼ venous thromboembolism.
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The ICON7 study showed an overall PFS advantage for patients
receiving bevacizumab of 2.4 months but in a pre-planned analysis
of a high-risk subgroup (suboptimally debulked stage III and all
stage IV patients, to match and corroborate GOG218) the
difference in PFS was 10.5 (control arm) vs 15.9 months (see
Table 1). In all, 67% of the study population in the GOG218 trial
were directly comparable to this group as only 33% were optimally
(o1 cm) debulked (25% were stage IV). A final analysis of OS in
ICON7 is planned for 2013 but the regulatory authorities requested
an interim analysis of OS data, ahead of the required number of
events, which was presented in 2012. Analysis of these data in the
suboptimally debulked stage III and stage IV patient subset showed
a statistically significant OS benefit of 8 months for the group
receiving additional maintenance bevacizumab compared with the
group receiving chemotherapy alone (HR 0.64, P¼ 0.002)
(Kristensen et al, 2012). These results indicate that disease stage
could play a critical role in how tumours respond to VEGF
pathway inhibition. However, there is concern as to how cancers
might respond when VEGF pathway inhibition stops, perhaps
triggering rapid regrowth with the potential for harm (Ebos et al,
2009). Clinical studies to date with VEGF-neutralising antibodies
have not shown increases in regrowth after treatment discontinua-
tion (Miles et al, 2011).
WHAT DOSE?: 15MGKG1 VS 7.5MGKG1 Q3W
The efficacy of the two doses of bevacizumab is very similar (or
comparable) in the ICON7 suboptimally debulked stage III/stage
IV subset and the GOG218 population, suggesting that the higher
dose of 15mg kg 1 q3w is unnecessary and that there is no
observable dose response above 7.5mg kg 1 q3w. While the higher
dose did not appear to cause significantly more adverse events in
GOG218, there is a trend towards a higher incidence of
hypertension among patients treated with the 15mg kg 1 dose,
in the relapse studies, but the median time of onset was after 16
cycles of bevacizumab, suggesting a cumulative effect (Aghajanian
et al, 2012, abstract). Thus, the consensus among treating UK
clinicians, despite the European licence, is that bevacizumab should
be used at a dose of 7.5mg kg 1 in first-line patients with
suboptimally debulked disease or inoperable and stage IV patients
particularly as there is no obvious benefit seen with the higher
dose in GOG218 in this setting. We will be encouraging the
National Institute for Clinical Excellence (NICE) to use this dose
when assessing its use in first-line ovarian cancer.
The 2011 Cochrane review of bevacizumab in ovarian cancer
concluded that from the data available, bevacizumab treatment in
first-line OC does not prevent progression, but delays it (Gaitskell
et al, 2011). Examining the newer data from GOG218 and ICON7
more closely suggests that bevacizumab does not benefit patients
who are optimally debulked (i.e., better prognosis), supporting the
concept that different disease ‘stages’ could influence the response
of tumours to anti-vascular interventions. This correlates with
more mature data from colorectal cancer where the AVANT and
C08 trials showed no benefit (in disease-free intervals) from the
addition of adjuvant bevacizumab to patients with stage II/III
colorectal cancers. Indeed, data from the AVANT trial suggested
that bevacizumab increased the adverse events in these patients
(de Gramont et al, 2011).
Suboptimally debulked stage III and IV patients represent 40%
of the presenting ovarian cancer population, all of whom have a
very high chance of progression; 50% do so within 6 months of
completing first-line treatment. Responses seen among this
population in the ICON7 and GOG218 trials suggest that these
patients would achieve an extra 6–8 months PFS if bevacizumab is
given as part of their first-line treatment with chemotherapy and
maintained until progression. Delaying progression by 6–8 months
in a group where half achieve o6 months remission, with current
standard treatment, is a significant advance.
There are a number of important outstanding questions about
the role of bevacizumab therapy in first-line treatment of ovarian
cancer: the duration of maintenance treatment, the effect of
additional bevacizumab to dose dense cytotoxics, its use when
considering interval debulking surgery and its addition to
intraperitoneal therapy (IP). Two trials, OCTAVIA—7.5mg kg 1
dose and GOG262 (NCT01167712)—15mg kg 1 dose, will
evaluate the efficacy of pairing bevacizumab with dose dense
first-line chemotherapy. Data presented at ASCO 2012 have
confirmed the safety of this combination (carboplatin q 21d/weekly
paclitaxel/bevacizumab). GOG252 (NCT00951496) completed
recruitment of 944 patients in April 2011, which confirms the
feasibility of concurrent bevacizumab with IP chemotherapy. All
treatment arms in this trial contained intravenous bevacizumab
and it will be interesting to compare results of this IP/IV platinum
and weekly paclitaxel trial with existing data on IP therapy.
However, there is no study that is directly asking whether the
advantages of either intraperitoneal or dose dense first-line therapy
can be enhanced by the addition of bevacizumab.
The updated JGOG data confirming continued OS advantage, at
6 years, for dose dense paclitaxel with 3-weekly carboplatin is likely
to make this schedule the treatment of choice in first line, pending
corroboration from the ICON8 study (Katsumata et al, 2012).
ICON8, however, does not include bevacizumab and if this trial is
to complete, this issue will need addressing urgently. Plans to
modify the existing MRC sponsored ICON8 study to incorporate
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Figure 1. Comparison of the Kaplan–Meier curves for PFS between GOG218 and the high-risk subgroup of ICON7.
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the addition of bevacizumab yet retain a third arm of dose dense
therapy without bevacizumab are most attractive, but execution of
these may be challenged by austerity measures.
Two trials, BOOST (AGO-OVAR-16/17, NCT01462890) and
RoSiA (NCT01239732) are both examining the feasibility and
possible benefits of extending the duration of maintenance
bevacizumab (15mg kg 1) to 30–36 months.
BEVACIZUMAB IN RELAPSED OVARIAN CANCER
Platinum-sensitive relapse. Bevacizumab (15mg kg 1) has also
recently been shown (OCEANS, NCT00434642) to improve PFS in
patients with platinum-sensitive relapse, when given in conjunc-
tion with carboplatin and gemcitabine for six (up to 10) cycles then
as single-agent maintenance until disease progression (Aghajanian
et al, 2012). In all, 484 patients with platinum-sensitive relapsed
ovarian cancer (ROC) were randomised to receive carboplatin and
gemcitabine with or without bevacizumab, which was continued as
maintenance until disease progression. No patient received prior
bevacizumab. An updated overall safety profile, after an additional
11 months, was similar to that seen at the time of the PFS analysis;
proteinuria and hypertension resolved upon discontinuation of
bevacizumab in the majority of patients (Aghajanian et al, 2012,
abstract).
Results confirmed an advantage for those receiving bevacizumab
extending the PFS in this group by 4 months, Po0.0001.
Suprisingly, no OS benefit has been shown (HR 1.027 at September
2011 analysis), which could be explained partly by crossover but
possibly also because most of these patients had several further
lines of chemotherapy. Could bevacizumab have a similar impact
as another line of chemotherapy, but with a very different toxicity
profile?
Platinum-resistant relapse. Phase II exploratory studies of
bevacizumab in ovary cancer indicated benefit even in patients
who had failed 43 lines previous chemotherapy and/or were
‘platinum resistant’. Partial response rates of 16–21%, with 27–38%
of patients alive and progression free at 6 months, can be achieved
(Burger et al, 2007; Cannistra et al, 2007). Several other
retrospective reports detailing bevacizumab therapy in a further
140 patients, confirm a median overall response rate of 57% (range
53–60%) for patients with ROC who have received a median of 4.5
previous cytotoxic therapies (Horsman et al, 2006; Chura et al,
2007; Hurt et al, 2009; Sfakianos et al, 2009). However, G3–4
toxicities occurred in 23–24% of these populations with a median
incidence of gastrointestinal perforation (GIP) of 3% (range 0–7%)
and on average these heavily treated platinum-resistant patients
only gained a progression-free survival of 4 months (OS of 10–20
months). A randomized trial of chemotherapy with and without
bevacizumab (AURELIA) in patients with platinum-resistant
ovarian cancer was presented earlier this year (Pujane-Lauraine
et al, 2012). This reported an increase in response rate (Po0.001)
and a doubling of PFS from 3.4 months to 6.7 months (HR 0.48) in
those patients who received bevacizumab in addition to single-
agent chemotherapy. The safety profile of bevacizumab in this
study was consistent with previous experience in the first- and
second-line settings (with a low incidence of GI perforation) but
patients at high risk of GI perforation were excluded from this
study. Overall survival data are expected in 2013.
Bevacizumab beyond progression. A major omission in the study
of bevacizumab in other tumour types such as colorectal cancer is
the lack of prospective randomized trials to address the question of
whether continuing anti-angiogenic therapy after progression and
simply introducing alternative cytotoxic treatment is of any
additional benefit in terms of PFS and OS. Observational studies
in colorectal cancer in the phase IV setting have suggested that this
is the case with an OS advantage of 9–12 months for those who
continue bevacizumab beyond progression (Grothey et al, 2008;
Cohn et al, 2010). Although there have been a couple of very small
single-arm prospective studies that corroborate this (Nakayama
et al, 2012), it becomes somewhat unethical to run the randomized
large scale phase III trials required to confirm these data and it is
most likely that in colorectal cancer the area will remain
controversial. A similar situation exists for herceptin in breast
cancer (Pegram and Liao, 2012). In ovarian cancer, however, a
prospective randomized trial (ENGOT-ov17/MITO 16/MaNGO 2)
started recruitment in January 2012 and 470 platinum-sensitive
patients progressing after bevacizumab in the first-line setting will
be randomized to receive their second-line chemotherapy with or
without additional bevacizumab at 15mg kg 1. Patients will be
stratified by bevacizumab-free interval (o or 416 weeks) and
platinum-free interval (6–12 vs 412 months). Results will be
eagerly awaited by patients and doctors alike although if they
suggest that bevacizumab should be continued, are likely to
generate further questions about dose, duration and perhaps most
importantly the economic viability of such a strategy.
TOXICITY
Common toxicities related to bevacizumab include hypertension,
proteinuria, haemorrhage and arteriovenous thromboembolic
phenomena. Exploration of the frequency of occurrence and
management of toxicities of bevacizumab in a variety of other solid
tumours are described in detail in Miles et al (2010). Selected
toxicity from the pivotal bevacizumab trials in ovary cancer are
detailed in Table 2. Sections detailing the common toxicities with
particular reference to ovarian cancer data appear below.
HYPERTENSION
Hypertension is the most common toxicity seen with bevacizumab
therapy and this occurs in 10–20% of treated patients. Looking at
all the trials published to date in ovarian cancer, the incidence of
hypertension seems to rise with cumulative exposure to bevacizu-
mab and is more common in patients receiving the higher
(15mg kg 1) doses (Burger et al, 2011; Perren et al, 2011;
Aghajanian et al, 2012, Pujade-Lauraine et al, 2012). In breast
cancer, a recent meta-analysis showed that hypertension and
proteinuria were the most relevant risks associated with the use of
bevacizumab (summary odds ratios of 27.68 for proteinuria and
12.76 for hypertension) but these events were rarely clinically
significant (Cortes et al, 2012).
VTE/ATE
Bevacizumab does not increase the risk of venous thromboembo-
lism; in a recent analysis of46000 patients treated in 10 different
non-ovarian randomized cancer trials and compared with controls,
the thromboembolic risk varied only according to different tumour
type (Hurwitz et al, 2011). This is not quite born out by the
evidence from the bevacizumab trials performed in ovarian cancer
to date, where there does appear to be a slightly increased risk of
VTE in patients receiving additional bevacizumab - see Table 2.
It is reported that the incidence of VTE events in patients with
advanced ovarian cancer range between 11% and 42% (in a clear
cell ovarian cancer subgroup) (Duska et al, 2010; Khorana et al,
2012). However, bevacizumab with chemotherapy has been shown
to carry a greater risk of ATE than chemotherapy alone in a pooled
analysis (n¼ 1745) of five non-ovarian cancer trials, especially in
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patients over the age of 65 years (Cassidy et al, 2010) But in pivotal
trials, including ovary cancer trials, stroke, TIA and myocardial
infarction only occurred in p3% of patients. Adverse events from
GOG218 and OCEANS would suggest that the combination of
chemotherapy with bevacizumab carries a higher ATE risk than
maintenance bevacizumab alone (Table 2). If ATE occurs,
bevacizumab should be discontinued.
WOUND HEALING
The approximate mean elimination half life of bevacizumab is 18–
20 days; published clinical trials have taken this into account so
that bevacizumab therapy is delayed until 428 days from any
planned surgery. There is no evidence of any greater incidence of
wound healing problems in published or ongoing trials in any
tumour type to date that involve interval surgery for bevacizumab-
treated patients (Okines et al, 2011; Javier Cortes et al, 2012). The
GOG213 (NCT00565851) study, carboplatin and paclitaxel for
platinum-sensitive relapse with or without bevacizumab after
optional secondary debulking surgery, will report a more accurate
risk with respect to wound healing in ROC patients.
GASTROINTESTINAL PERFORATION
The pathophysiological mechanism by which bowel perforations
occur during bevacizumab therapy is unknown but possible
mechanisms include
 necrosis of tumour on serosal surfaces with weakening of
adjacent intestinal wall,
 bowel injury at surgery with delayed wound healing,
 vasoconstriction and/or thrombosis of intestinal mesenteric
vessels,
 other GI-related risk factors such as bowel obstruction or
diverticulitis,
 prior surgical interventions.
These proposed mechanisms of action support the trend in
those receiving bevacizumab for ovary cancer where higher rates of
GIP occur in patients with documented serosal plaques or bowel
obstruction at study entry.
The reported incidence of perforations in the single-arm phase
II trials of bevacizumab in recurrent ovarian cancer varies widely,
but is as high as 11% in a study where 40 of the 44 patients had
radiographic bowel involvement at study entry (Cannistra et al,
2007). However, in an analysis of combined data in relapsed ovary
cancer patients, the overall risk with bevacizumab treatment was
5.4% (Han and Monk, 2007). Overall this represents a higher risk
than in metastatic colorectal cancer patients treated with
bevacizumab where it is estimated to be 1.9% (Kabbinavar et al,
2012).
Sfakianos et al (2009) remind us that there is an underlying
incidence of GIP in patients with multiply ROC, whether or not
they have received bevacizumab. Their retrospective review puts
the relative risk for developing a GIP/fistula as a consequence of
the addition of bevacizumab to further chemotherapy, in this
setting at 1.09. It does not diminish the potentially devastating
consequences of GIP with a 30-day mortality of 50% (Miller et al,
2001; Diaz et al, 2010).
The entry criteria for the single-agent Burger study of 2007
mandated 2 or fewer lines of previous therapy, which is perhaps
why no GIP was reported. No protocol-specified GIP was reported
in the OCEANS study either, where patients had not received any
chemotherapy for relapse. However, GIP occurred in two patients
after progression in this study, both having received bevacizumab
42 months prior to this. Other studies suggest that GIP and
enteral fistulae occur more frequently during bevacizumab therapy
in those who have had X3 lines of therapy, known fistulae or
Table 2. Selected adverse events for bevacizumab in pivotal ovary cancer trials: GOG218, ICON7 and OCEANS
GOG218
% affecteda
ICON7
% affectedb
OCEANS
% affectedc
CPþplacebo CPþB15-4 B15 CP CPþB7.5-4 CGþplacebo CGþB15-4
Patients, n 601 483 608 464 753 745 233 247
Cycles 2906 4059 2891 4677 NR NR NR NR
Treatment phase Cycles 2–6 Cycles 7–22 Cycles 2–6 Cycles 7–22 Overall Overall Overall
Selected adverse events (grade when limited)
GI events (perforation/fistula/
necrosis/leak) (4G2)
1.0 o1.0 2.5 0.2 o1 1.3 o1 o1d
Hypertension (XG2) 3.5 4.6 9.9 17.0 2.1 18.3 0.4 (XG3) 17.8 (XG3)
Proteinuria (XG3) 0.3 0.4 0 2.2 o1 o1 0.9 9.7
Venous Thromboembolic
Event (VTE)
4.3 1.9 4.4 3.0 1.7XG3 4.3XG3 2.6XG3 4XG3
Arterial Thromboembolic
Events (ATE) (all grades)
0.7 0.2 0.5 0.2 1.5 3.6 0.9 2.8
Wound healing complications 1.8 1.2 2.1 1.1 2.1 5.0 0XG3 0.8XG3
CNS bleeding (all grades) 0 0 0 0.4 0 o1 0.4 0.8
Non-CNS bleeding (XG3) 0.5 0.4 1.6 0.6 o1 o1 0.9 5.7
RPLS (all grades) 0 0 0 0.2 o1 o1 0 0.8
Abbreviations: B¼bevacizumab 7.5 or 15mgkg 1; CG¼ carboplatin and gemcitabine; CNS¼ central nervous system; CP¼ carboplatin and paclitaxel; GI¼gastrointestinal; NR¼not
recorded; RPLS¼ reversible posterior leucoencephalopathy syndrome.
aBurger et al, 2011; bPerren et al, 2011; cAghajanian et al, 2012, abstract; dTwo GI perforations occurred 69 days after last Bev dose.
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significant bowel wall involvement. Rectovaginal nodularity has an
association with an increased incidence of GIP in ovarian cancer
patients, even taking imaging findings into account, which may
represent a clinical manifestation of significant serosal involvement
elsewhere (Richardson et al, 2010).
By contrast, there was only a 1–1.5% increase in GI perforations
recorded in the chemotherapy plus bevacizumab arms of the first-
line GOG218 and ICON7 trials compared with the 1% incidence in
patients on chemotherapy alone. GOG218 details (shown in
Table 2) reveal that this slight increased incidence of GIP among
those treated with additional bevacizumab equalises across both
arms once maintenance bevaciaumzab/placebo is established,
suggesting that it is the combination of agents that results in a
higher risk for this population.
SMALL MOLECULE TYROSINE KINASE INHIBITORS
There are now several small molecule inhibitors of VEGFR
tyrosine kinase (TKI) that have been shown to be active in ovarian
cancer. Many of these are multitargeted kinases inhibiting the
VEGFR family and others. When assessing TKIs in patients with
assessable disease, classical measures of activity such as complete
and partial response may not be as informative as in chemotherapy
studies, for example in two single-agent studies, one with cediranib,
the other pazopanib, only 18% patients obtained a PR yet the PFS
was 5.2 months and 113 days, respectively (Matulonis et al, 2009;
Friedlander et al, 2010). The populations of both studies were
multiply relapsed, platinum-resistant patients, the end point of the
Matulonis study was determined as ‘clinical benefit rate’ (improved
in 30%)– the sum of PR (17%) and SD (13%) patients. Other phase
II studies with sunitinib or sorafenib have reported similar results
(Biagi et al, 2011; Matei et al, 2011). All these studies, conducted in
a heterogenous population, make interpretation of response, or
even PFS difficult. The side effects of these drugs are similar, with
hypertension, fatigue and diarrhoea being most commonly found.
Nevertheless, as experience grows most of these are manageable by
altering the dose or schedule, and introducing short ‘drug holidays’
as part of longer-term treatment.
Randomised trials provide a better approach to evaluating this
class of drugs, eliminating some of the bias of patient selection and
allowing a more objective assessment of side effects in a
population that often have disease-related symptoms. In a
randomised maintenance trial nintedanib (BIBF1120)/placebo
was given to patients who had responded and completed
treatment for relapsed disease (Ledermann et al, 2011). The trial
was statistically powered to assess PFS at 36 weeks; this was 16%
in patients receiving nintedanib and 5% on placebo (HR 0.65,
P¼ 0.06) and the drug was taken forward to phase III in the first-
line setting. There was a higher rate of nausea, vomiting, diarrhoea
and disturbed liver function tests in patients on nintedanib but
only rarely of clinical significance; most patients continued
treatment until PD.
Other larger phase III trials are also in progress, two in first-line
treatment (pazopanib/placebo, NCT00866697 and nintedanib/
placebo, AGO-OVAR-12, NCT01015118) and one at first platinum-
sensitive relapse (cediranib/placebo, ICON6, NCT00532194).
Virtually all of these trials involve concomitant TKIs with
chemotherapy, but pazopanib is unable to be given with many
cytotoxics due to excess adverse events. The TKIs are then
continued as maintenance for up to 2 years or PD in each trial. The
first-line trials have completed recruitment; PFS is the primary end
point. In ICON6, an academically led 3-arm study in relapse where
two experimental arms of cediranib were given with chemotherapy
then as maintenance until progression, or only with chemotherapy,
switching to placebo maintenance, the trial end point has been
modified to have PFS as the primary end point as the manufacturer
decided not to develop the drug further. The trial is still ongoing,
but closed to recruitment with 486 patients.
ANGIOPOEITIN PEPTIBODIES
Angiopoetins are circulating protein growth factors (Ang-1/Ang-2)
that promote angiogenesis by interacting with Tie2 receptors. The
anti-angiopoetin 1/2 peptibody (a first-in-class peptide-Fc fusion
protein), AMG386, given in combination with weekly paclitaxel
has demonstrated prolongation of PFS in a recent randomized
phase II trial (4.6–7.2 months, HR 0.76) (Karlan et al, 2012). Side
effects included oedema, hypertension and thromboembolic
events. A phase III study, TRINOVA-1 (NCT01204749) has closed
to recruitment, randomizing patients with ROC between AMG 386
or placebo in combination with weekly paclitaxel. The primary
outcome measure is progression-free survival. Phase II trials of
PLD with and without AMG 386 in patients with platinum-
resistant ROC are also underway (TRINOVA-2 NCT01291254) as
is a phase III double blind, placebo-controlled study of AMG386
with carboplatin and paclitaxel in patients with newly diagnosed
ovarian cancer (TRINOVA-3 NCT01493505).
VASCULAR DISRUPTIVE AGENTS
Conventionally, the molecules known as VDAs are either
derivatives of flavone acetic acid that are thought to act by
invoking cytokine release such as TNFa or are tubulin-binding
agents such as combretastatin. The selectivity of the tubulin-
binding agents is thought in part to be due to the rapid division of
endothelial cells but these agents also cause distortion of immature
endothelial cells which lack a pericyte coating. This distortion
induces thrombosis and vessel collapse (Horsman and Siemann,
2006). VDAs have minimal single-agent activity as despite causing
necrosis of the main cancer mass, a viable rim is left, which
repopulates the cancer. It appears that VDAs eliminate cells that
are less well vascularised where the delivery of systemically
administered chemotherapeutic drugs is limited, and which are
resistant to radiotherapy, while cytotoxic drugs exert their greatest
effects on cells in the viable rim of tumour tissue that survive the
VDA treatment. Preclinical and some early clinical results suggest
that greater efficacy can be obtained as combination therapy—
VDAs with cytotoxic agents, active against the rapidly repopulat-
ing tumour rim, or with VEGF inhibitors that act by blocking
repopulation with circulating endothelial progenitor cells. Unlike
the chronic dosing schedule required to prevent angiogenesis,
VDAs should be effective given as intermittent doses. Early single-
arm phase II studies in patients have shown that the addition of
VDAs such as vadimezan (DMXAA) or fosbretabulin (CA4P) to
standard chemotherapy is well tolerated and appears to produce a
higher response rate in the populations studied to date, for
example 29% response by RECIST or GCIG CA125 criteria in
platinum-resistant patients (McKeage, 2011; Zweifel et al, 2011).
Recruitment to two phase II studies, ombrabulin/placebo with
conventional carboplatin and paclitaxel chemotherapy and
bevacizumab with or without fosbretabulin are underway in
platinum-sensitive ovarian cancer in the United States
(NCT01305213, NCT01332656).
CHEMOTHERAPY SCHEDULING
Weekly paclitaxel. Many chemotherapy drugs are believed to
possess anti-angiogenic effects themselves (Miller et al, 2001). The
Targeted anti-vascular therapies in ovary cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2012.541 255
mechanism is that tumour endothelial cells are likely to be actively
cycling at the site of (neo)angiogenesis and thus susceptible to
chemotherapy-induced damage; this damage is less likely to be
repaired with repeated weekly chemotherapy than with conven-
tional 3-weekly administrations. Belotti et al (1996) first reported
that low-dose paclitaxel was specifically toxic to endothelial cells;
additional paclitaxel effects on the endothelial cells include cell-
cycle delay rather than arrest, alterations in microtubule dynamics
and blocking of bFGF and VEGF-induced vascularisation as well as
a reduction of new vessel infiltration in vitro (Belotti et al, 1996;
Pasquier et al, 2005). Only one study has attempted to measure
vascular flow in women with ovarian cancer treated with paclitaxel,
demonstrating a reduction in endothelial flow-mediated dilatation
(Vassilakopoulou et al, 2010).
In clinical practice, single agent, weekly paclitaxel has activity in
relapsed, platinum-resistant ovarian cancer with response rates
ranging from 25% to 55%. However, median progression-free
survival is relatively poor atB6 months (Le et al, 2006). There has
not been a formal comparison of weekly paclitaxel with other
licensed drugs for this platinum-resistant setting such as pegylated
liposomal doxorubicin. It is well reported, however, that the
addition of other chemotherapy agents (e.g., carboplatin, AUC5
q4/52, or topotecan, 3mgm 2 per week) to weekly paclitaxel in
platinum-resistant ovarian cancer, increases toxicity and does not
improve progression-free survival (Lortholary et al, 2011). Two
more recent publications suggest that any effect that weekly
paclitaxel might have, can be enhanced by the addition of vascular
targeting agents such as bevacizumab or AMG386 (O’Malley et al,
2011; Karlan et al, 2012).
METRONOMIC THERAPY
It is thought that regular low doses of oral chemotherapy
(metronomic) might act in a similar mode to that described for
weekly paclitaxel, or perhaps through the induction of thrombos-
pondin, an endogenous inhibitor of angiogenesis (Bornstein,
1995). Colorectal and breast oncologists have been using low dose
continuous 5 fluorouracil for decades and more recently oral
capecitabine. Other agents, such as etoposide, methotrexate and
cyclophosphamide, have also shown activity when given metro-
nomically in a number of different tumour types. It is hoped that
the addition of anti-angiogenic agents to metronomic chemother-
apy will act synergistically to improve response rates and outcomes
in ovarian cancer. For example, bevacizumab in combination with
metronomic cyclophosphamide resulted in 56% of 70 platinum-
resistant patients remaining alive and progression free at 6 months,
suggesting an enhanced response rate (P¼ 0.017) (Garcia et al,
2008). Good preclinical evidence also exists for oral topotecan
with pazopanib and this prompted a phase I trial, recently reported
at ASCO 2012 (Hashimoto et al, 2010; Merritt et al, 2010;
Tillmans et al, 2012). Treatment of patients with recurrent
(platinum resistant) ovarian cancer with metronomic cyclopho-
sphamide and other agents such as methotrexate, celecoxib and
tamoxifen have also been reported (Hall and Rustin, 2010).
Combination trials using metronomic cyclophosphamide with oral
anti-angiogenic agents such as pazopanib and BIBF1120 are also
underway.
FUTURE DIRECTIONS FOR ANTI-ANGIOGENICS
The main current issues with anti-angiogenic therapy are a lack of
accurate predictors of therapeutic efficacy and the inability to
prevent resistance to treatment. Pharmacoeconomic concerns are
also a major problem in relation to the clinical use of VEGF
inhibitors (Hensley, 2011). Further studies of bevacizumab with
chemotherapy are warranted in order to optimise the dose and
duration of maintenance therapy, and to identify the best time to
use this agent, first-line, relapse or both. Clarification of the role of
single-agent bevacizumab in managing ascites is required (Kobold
et al, 2009). The most promising combinations of anti-angiogenic
agents with standard chemotherapy also require further explora-
tion. Most importantly, however, identification of predictive
biomarkers in ovary cancer patients is urgently needed for
‘individualisation’ of VEGF-targeted therapy. The most promising
new assay measures soluble, low-molecular weight VEGF-A
isoforms that was shown to be of predictive value in the
retrospective evaluation of breast, pancreatic and gastric cancer
specimens (Jayson et al, 2011). Prospective evaluations in breast
and lung cancer are under way, however, no data are available with
ovarian cancer so far.
CONCLUSION
The treatment of patients with ovarian cancer continues to be
challenging. Opportunities identified in the molecular microcosm
of neoplastic pathways yields many promising targets. Evaluation
of the action of a range of targeted agents in ovarian cancer is
underway. The anti-angiogenic drugs are driving the field with the
recent licensing of bevacizumab in first- and second-line treatment
in Europe. The activity of bevacizumab in ROC evokes consider-
able potential for future therapeutic strategies although refinement
of details such as optimal timing of treatment, combinations with
other agents, duration of treatment and payment for this is
urgently required to inform safest and best practice. The work has
just begun!
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